Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

- Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death) - Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in